LyfeSci Research & Innovation Acquires Clinically Media to Expand Patient-Centric Clinical Trial Capabilities
News > Business News
Audio By Carbonatix
9:30 AM on Monday, January 12
The Associated Press
CHICAGO--(BUSINESS WIRE)--Jan 12, 2026--
LyfeSci Research & Innovation, a full-service clinical research organization (CRO), announces the acquisition of Clinically Media, a patient recruitment company specializing in data-driven, inclusive enrollment strategies. The acquisition integrates patient recruitment directly into LyfeSci’s CRO model, expanding its end-to-end clinical trial capabilities.
Clinically Media’s expertise across dermatology, neurology, and psychiatry supports LyfeSci’s current areas of focus while strengthening its ability to expand into additional therapeutic areas.
The acquisition reflects LyfeSci’s continued commitment to building more patient-centric clinical trials and addressing one of the industry’s most persistent challenges: timely and representative patient enrollment.
“Patient recruitment is no longer a downstream activity, it is central to study execution,” said Dr. Tapan Parikh, Founder and CEO of LyfeSci. “By integrating Clinically Media into LyfeSci, we can connect study design decisions, site selection strategy, and recruitment execution in a more coordinated way, supporting stronger planning and execution for sponsors.”
Clinically Media is known for its targeted digital outreach, community-based recruitment strategies, and focus on patient experience. Under LyfeSci, these capabilities will be embedded into protocol feasibility, site selection, and ongoing enrollment optimization.
“Joining LyfeSci gives Clinically Media the opportunity to continue scaling thoughtfully while staying true to our mission of improving the experiences of patients participating in clinical research,” said Victoria Donovan, Founder and CEO of Clinically Media. “Together, we are positioned to deliver efficient and sustainable patient recruitment that benefits sponsors, research sites, and patients.”
The acquisition expands LyfeSci’s service offerings to provide integrated support for trial planning and execution, including protocol feasibility and recruitment forecasting, site-centric enrollment support, and data-driven recruitment strategies designed to support inclusive patient participation.
Clinically Media will continue operations under the LyfeSci Research & Innovation brand, with Clinically Media’s team and expertise fully integrated into LyfeSci’s CRO services.
About LyfeSci Research & Innovation
LyfeSci is a physician-founded CRO dedicated to transforming clinical research through patient-centered methodologies and strong partnerships with clinical sites and sponsors. By integrating clinical expertise with patient-focused innovation, LyfeSci advances therapeutic development and improves health outcomes across multiple therapeutic areas on a global scale. The company brings experience across a broad range of therapeutic indications, with deep expertise in dermatology and central nervous system (CNS) research, including aesthetic medicine, dermatology, psychiatry, and neurology. Clinically Media partners with sponsors, CROs, and research sites to deliver patient-centric enrollment strategies tailored to the unique needs of each study.
About Clinically Media
Clinically Media is an award-winning, full-service agency specializing in cost-efficient, data-driven patient recruitment in clinical research.
View source version on businesswire.com:https://www.businesswire.com/news/home/20260109474518/en/
CONTACT: Media Contact:
Myra Zerr-Korolev
Director of Operations
KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH SCIENCE OTHER SCIENCE RESEARCH CLINICAL TRIALS
SOURCE: LyfeSci Research & Innovation
Copyright Business Wire 2026.
PUB: 01/12/2026 09:30 AM/DISC: 01/12/2026 09:30 AM
http://www.businesswire.com/news/home/20260109474518/en
